Neu­ro­crine ax­es Take­da-part­nered de­pres­sion pro­gram, switch­es fo­cus for seizure drug af­ter PhII fail­ures

Neu­ro­crine Bio­sciences has been hit with a pair of mid-stage fail­ures for its part­nered can­di­dates in ma­jor de­pres­sive dis­or­der (MDD) and fo­cal on­set seizures (FOS), lead­ing the biotech to wind down the MDD pro­gram al­to­geth­er and home in on a much small­er mar­ket op­por­tu­ni­ty for the seizure can­di­date.

The place­bo-con­trolled Phase II TERP­SIS tri­al was eval­u­at­ing Take­da-part­nered drug NBI-1065846 in 93 MDD pa­tients with an­he­do­nia, which is the in­abil­i­ty to feel plea­sure. The treat­ment did not meet the pri­ma­ry end­point of change in an­he­do­nia sever­i­ty, mea­sured by the Di­men­sion­al An­he­do­nia Rat­ing Scale score at 57 days. The com­pa­ny said it is dis­con­tin­u­ing fur­ther de­vel­op­ment of the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER